Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Recurrent Low-Grade Serous Ovarian or Peritoneal Cancer
NCT00551070Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2007
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in low-grade serous ovarian carcinoma (LGSOC), serous peritoneal carcinoma (PPSC), sponsored by National Cancer Institute. Started Dec 2007; status: completed.
02
Drugs
selumetinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on NCT00551070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551070.